文献速递细菌感染、耐药与抗菌药物医院感染防控

马拉维伤寒疫苗加速联盟:Vi-TCV在儿童中的III期随机双盲对照试验

Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi.
PubMed 文献 · Clin Infect Dis · 2019-01-01

BACKGROUND: Typhoid fever is an acute infection characterized by prolonged fever following the ingestion and subsequent invasion of Salmonella enterica serovar Typhi (S. Typhi), a human-restricted pathogen.…

要点

  • Vi-TCV在非洲高负担地区儿童中的临床效力尚待本试验验证
  • 主要结局为被动监测至少2年的血培养确诊伤寒
  • 亚组评估免疫应答与不良事件,以补充安全性数据

核心结论

  • 该试验旨在评估Vi-TCV在马拉维9月龄至12岁儿童中的临床效力,为非洲首次TCV效力试验。

研究设计与样本

  • 其中600名儿童纳入免疫原性与反应原性亚组,评估安全性和免疫应答。

关键数值与推荐

  • 主要结局为被动监测至少2年期间血培养确诊的伤寒沙门菌感染。
  • 亚组在接种前及接种后2个时间点采血检测免疫应答,并主动随访不良事件和严重不良事件。

临床怎么用

  • 若证实有效,单剂Vi-TCV可引入高负担或耐药显著国家,保护儿童并减少抗菌药物使用。
  • 该试验旨在展示TCV在地方性流行环境中的影响和规划性使用。

局限性

  • 本文为试验方案摘要,尚未报告效力、免疫原性或安全性结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Typhoid fever is an acute infection characterized by prolonged fever following the ingestion and subsequent invasion of Salmonella enterica serovar Typhi (S. Typhi), a human-restricted pathogen. The incidence of typhoid fever has been most reported in children 5-15 years of age, but is increasingly recognized in children younger than 5 years old. There has been a recent expansion of multidrug-resistant typhoid fever globally. Prior typhoid vaccines were not suitable for use in the youngest children in countries with a high burden of disease. This study aims to determine the efficacy of a typhoid conjugate vaccine (TCV) that was recently prequalified by the World Health Organization, by testing it in children 9 months through 12 years of age in Blantyre, Malawi. METHODS: In this Phase III, individually randomized, controlled, double-blind trial of the clinical efficacy of TCV, 28 000 children 9 months through 12 years of age will be enrolled and randomized in a 1:1 ratio to receive either Vi-TCV or a meningococcal serogroup A conjugate vaccine. A subset of 600 of these children will be further enrolled in an immunogenicity and reactogenicity sub-study to evaluate the safety profile and immune response elicited by Vi-TCV. Recruiting began in February 2018. RESULTS: All children will be under passive surveillance for at least 2 years to determine the primary outcome, which is blood culture-confirmed S. Typhi illness. Children enrolled in the immunogenicity and reactogenicity sub-study will have blood drawn before vaccination and at 2 timepoints after vaccination to measure their immune response to vaccination. They will also be followed actively for adverse events and serious adverse events. CONCLUSIONS: The introduction of a single-dose, efficacious typhoid vaccine into countries with high burden of disease or significant antimicrobial resistance could have a dramatic impact, protecting children from infection and reducing antimicrobial usage and associated health inequity in the world's poorest places. This trial, the first of a TCV in Africa, seeks to demonstrate the impact and programmatic use of TCVs within an endemic setting. CLINICAL TRIALS REGISTRATION: NCT03299426.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Meiring JE, Laurens MB, Patel P, et al. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi. Clin Infect Dis. 2019. PMID: 30845320. doi:10.1093/cid/ciy1103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。